Evelo Biosciences Inc (NASDAQ:EVLO)

9.99
Delayed Data
As of Apr 09
 -0.03 / -0.30%
Today’s Change
3.55
Today|||52-Week Range
19.93
-17.37%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$565.9M

Company Description

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases; EDP2939 for inflammation; and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Contact Information

Evelo Biosciences, Inc.
620 Memorial Drive
Cambridge Massachusetts 02139
P:(617) 577-0300
Investor Relations:

Employees

Shareholders

Individual stakeholders54.45%
Mutual fund holders22.33%
Other institutional12.57%

Top Executives

Simba GillPresident, Chief Executive Officer & Director
Mark BodmerChief Scientific Officer, President-R&D
Andrea ItanoSenior Vice President & Head-Research
Duncan McHaleChief Medical Officer
Chun ZhangHead-Technical Operations